These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21669126)

  • 1. Functional system scores provide a window into disease activity occurring during a multiple sclerosis treatment trial.
    Scott TF; You X; Foulds P
    Neurol Res; 2011 Jun; 33(5):549-52. PubMed ID: 21669126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between sustained disability progression and functional system scores in relapsing-remitting multiple sclerosis: analysis of placebo data from four randomized clinical trials.
    Scott T; Wang P; You X; Mann M; Sperling B
    Neuroepidemiology; 2015; 44(1):16-23. PubMed ID: 25634764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon beta1a (Avonex) treatment in multiple sclerosis: similarity of effect on progression of disability in patients with mild and moderate disability.
    Vermersch P; de Seze J; Stojkovic T; Hautecoeur P;
    J Neurol; 2002 Feb; 249(2):184-7. PubMed ID: 11985384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients.
    Rudick RA; Cutter GR; Baier M; Weinstock-Guttman B; Mass MK; Fisher E; Miller DM; Sandrock AW
    Mult Scler; 2005 Dec; 11(6):626-34. PubMed ID: 16323317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind randomized multicenter dose-comparison study of interferon-beta-1a (AVONEX): rationale, design and baseline data.
    Mult Scler; 2001 Jun; 7(3):179-83. PubMed ID: 11475442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the FIM instrument in a trial of intramuscular interferon beta-1a for disease progression in relapsing-remitting multiple sclerosis.
    Granger CV; Wende K; Brownscheidle CM
    Am J Phys Med Rehabil; 2003 Jun; 82(6):427-36. PubMed ID: 12820784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Rudick RA; Goodkin DE; Jacobs LD; Cookfair DL; Herndon RM; Richert JR; Salazar AM; Fischer JS; Granger CV; Simon JH; Alam JJ; Simonian NA; Campion MK; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Whitham RH
    Neurology; 1997 Aug; 49(2):358-63. PubMed ID: 9270562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
    Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
    Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective clinical and electrophysiological follow-up on a multiple sclerosis population treated with interferon beta-1 a: a pilot study.
    Feuillet L; Pelletier J; Suchet L; Rico A; Ali Cherif A; Pouget J; Attarian S
    Mult Scler; 2007 Apr; 13(3):348-56. PubMed ID: 17439904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.
    Fox EJ; Wynn D; Coles AJ; Palmer J; Margolin DH;
    J Neurol Sci; 2016 Apr; 363():188-94. PubMed ID: 27000249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
    Pokryszko-Dragan A; Bilińska M; Gruszka E; Dubik-Jezierzańska M
    Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple sclerosis and depression: influence of interferon beta therapy.
    Zephir H; De Seze J; Stojkovic T; Delisse B; Ferriby D; Cabaret M; Vermersch P
    Mult Scler; 2003 Jun; 9(3):284-8. PubMed ID: 12814176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.
    Sormani MP; Li DK; Bruzzi P; Stubinski B; Cornelisse P; Rocak S; De Stefano N
    Neurology; 2011 Nov; 77(18):1684-90. PubMed ID: 21975200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH
    Mult Scler; 1995 Jun; 1(2):118-35. PubMed ID: 9345462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Interferon beta-1a (Avonex TM): clinical and MRI impacts].
    Vermersch P
    Rev Neurol (Paris); 1999; 155 Suppl 2():S13-9. PubMed ID: 10367320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Open trial of the effectiveness of interferon beta 1a (Avonex) in multiple sclerosis. Clinical assessment using motor coordination tests].
    Selmaj K; Członkowska A; Kwieciński H; Losy J; Podemski R; Stelmasiak Z
    Neurol Neurochir Pol; 2003; 37(6):1163-83. PubMed ID: 15174231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing disability progression with the Multiple Sclerosis Functional Composite.
    Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW
    Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Static Posturography and Falls According to Pyramidal, Sensory and Cerebellar Functional Systems in People with Multiple Sclerosis.
    Kalron A; Givon U; Frid L; Dolev M; Achiron A
    PLoS One; 2016; 11(10):e0164467. PubMed ID: 27741268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.